Science Explorer Back to mapMap
Discussion
Topic · Oncology

Vascular Tumors and Angiosarcomas

Vascular Tumors and Angiosarcomas is a research topic within Oncology. Science Explorer counts 19k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the research and clinical aspects of vascular tumors, particularly angiosarcoma and epithelioid hemangioendothelioma. It covers topics such as treatment outcomes, diagnostic markers, genetic alterations, risk factors, and therapeutic options for various types of vascular tumors. The cluster also explores the impact of radiation therapy on the development of angiosarcoma and the role of liver transplantation in managing hepatic angiosarcoma.

  • Angiosarcoma
  • Epithelioid Hemangioendothelioma
  • Vascular Tumors
  • Radiation-Associated Angiosarcoma
  • Hepatic Angiosarcoma
  • Kimura Disease
  • Malignant Vascular Tumors
  • Pseudomyogenic Hemangioendothelioma
  • Metastatic Angiosarcomas
  • Primary Liver Sarcomas
Research works
19k
fractional, since 1950
In the world top 10%
1.9k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+3%
the tick is no change
Largest producer
United States
30% of the 10 largest, 2022-now
Vascular Tumors and Angiosarcomas

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Vascular Tumors and Angiosarcomas research?

By volume, the United States and China publish the most (724 and 534 works in 2022-now).

By volume, 2022-now

  1. 1 United States 724 works
  2. 2 China 534 works
  3. 3 India 319 works
  4. 4 Japan 254 works
  5. 5 Germany 101 works
  6. 6 Italy 100 works
  7. 7 Spain 97 works
  8. 8 United Kingdom 86 works
  9. 9 France 85 works
  10. 10 Brazil 78 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 30.4%China: 22.5%India: 13.4%Japan: 10.7%6 others listed: 23.0%30%largest
United States724 · 30.4%China534 · 22.5%India319 · 13.4%Japan254 · 10.7%6 others listed547 · 23.0%

Shares of the rows listed above, not of the whole node.

Which institutions lead Vascular Tumors and Angiosarcomas research?

By volume in 2022-now, All India Institute of Medical Sciences publishes the most Vascular Tumors and Angiosarcomas research, followed by Harvard University and Sichuan University.

By volume, 2022-now

  1. 1 All India Institute of Medical SciencesIndia 36 works
  2. 2 Harvard UniversityUnited States 33 works
  3. 3 Sichuan UniversityChina 32 works
  4. 4 Mayo ClinicUnited States 25 works
  5. 5 Peking UniversityChina 18 works
  6. 6 The University of Texas MD Anderson Cancer CenterUnited States 18 works
  7. 7 The Ohio State UniversityUnited States 17 works
  8. 8 Zhejiang UniversityChina 16 works
  9. 9 Shanghai Jiao Tong UniversityChina 16 works
  10. 10 Capital Medical UniversityChina 16 works

Who are the leading researchers in Vascular Tumors and Angiosarcomas?

The most-cited researchers publishing on Vascular Tumors and Angiosarcomas include Eric S. Lander, Robert John Tibshirani and Jun Wang.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 Robert John Tibshirani United States 396k citations
  3. 3 Jun Wang China 340k citations
  4. 4 Todd R. Golub United States 283k citations
  5. 5 Hagop M. Kantarjian United States 273k citations
  6. 6 Gordon Brent Mills United States 265k citations
  7. 7 Carlo La Vecchia Italy 258k citations
  8. 8 Alberto Mantovani Italy 224k citations
  9. 9 Kai You Wang China 224k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Vascular Tumors and Angiosarcomas?

The most cited paper in Vascular Tumors and Angiosarcomas is "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" (Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al., 1997), with 4,521 citations. Next come "Vascular endothelial growth factor (VEGF) and its receptors" (3,520) and "Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial" (2,123).

Most cited papers
#PaperReleasedCitations
1 Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al. · Cell Open access 1997 4,521
2 Vascular endothelial growth factor (VEGF) and its receptors Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch et al. · The FASEB Journal 1999 3,520
3 Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Winette T.A. van der Graaf et al. · The Lancet Open access May 2012 2,123
4 Follow-up study of thymomas with special reference to their clinical stages Akira Masaoka, Yasumasa Monden, Kazuya Nakahara et al. · Cancer Dec 1981 1,725
5 VEGF-targeted therapy: mechanisms of anti-tumour activity Lee M. Ellis, Daniel J. Hicklin · Nature reviews. Cancer Review 3 Jul 2008 1,683
All 100 most cited papers, with filters and sorting

Where is Vascular Tumors and Angiosarcomas research done?

The largest centres of Vascular Tumors and Angiosarcomas research in 2022-now are Beijing (China), New Delhi (India), Tokyo (Japan) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Cleveland.

Largest cities, 2022-now

  1. 1 BeijingChina 70 works
  2. 2 New DelhiIndia 46 works
  3. 3 TokyoJapan 44 works
  4. 4 New YorkUnited States 42 works
  5. 5 ChengduChina 41 works
  6. 6 ShanghaiChina 39 works
  7. 7 GuangzhouChina 33 works
  8. 8 LondonUnited Kingdom 30 works
  9. 9 HoustonUnited States 29 works
  10. 10 MoscowRussia 27 works

Where it is the local speciality

  1. ClevelandUS · 22.5 works5.0×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Vascular Tumors and Angiosarcomas than the world average.

See Vascular Tumors and Angiosarcomas on the map

Where is the best place to study Vascular Tumors and Angiosarcomas?

Among universities, judged by research, Harvard University, Sichuan University and Stanford University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 19.94%fractional works in this field (log) →share of work in the world top 10% →Sun Yat-sen UniversityHarvard UniversityStanford UniversitySichuan University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 81.126.7%3.7×33 -34.1%
2Sichuan UniversityChina 69.219.1%5.0×32 +65.3%
3Stanford UniversityUnited States 60.224.9%3.1×13 +14.8%
4Sun Yat-sen UniversityChina 56.426.8%2.5×15 +19.6%
5All India Institute of Medical SciencesIndia 54.64.5%11.5×36 +18.0%
6Columbia UniversityUnited States 54.326.3%2.6×8 +77.2%
7The Ohio State UniversityUnited States 54.215.4%5.1×18 +90.3%
8University of TorontoCanada 48.427.9%1.6×9 -21.6%
9Peking UniversityChina 47.810.9%3.1×18 +66.6%
10Zhengzhou UniversityChina 46.316.9%4.0×14 +28.3%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Vascular Tumors and Angiosarcomas, country by country

Is Vascular Tumors and Angiosarcomas research growing?

Output in 2022-2025 was 3% higher than in 2018-2021, peaking in 2021. The fastest-growing topics are Vascular Tumors and Angiosarcomas.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Vascular Tumors and Angiosarcomas as a percentage of every work published that year, 0.013% in 2024.

still counting0.010%0.020%0.030%Vascular Tumors and Angiosarcomas0.013% in 202519801990200020102020

Fractional works of Vascular Tumors and Angiosarcomas over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Vascular Tumors and Angiosarcomas10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Vascular Tumors and Angiosarcomas. Posts are plain text and can be reported.